ClinicalTrials.gg
RecruitingNCT07686835FIGURE-IMUpdated Jul 27, 2026

Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.

A Phase 2 interventional study of Dried chicory roots and Placebo in Melanoma (Skin) Stage IV, Melanoma (Skin Cancer) and Melanoma Metastatic, sponsored by Radboud University Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Radboud University Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Melanoma by Radboud University Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Melanoma · Radboud University Medical Center.

Planned enrollment
3rd of 11
70 · median 40
Started
2026
with 1 other
Phase 2
2 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Melanoma by Radboud University Medical Center, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 10th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 11 studies in Melanoma by Radboud University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Melanoma by Radboud University Medical Center, or all of them as a file.
02

Study summary

Previous research has shown that a higher fiber intake may have a beneficial effect on the intestinal health and improve the effectiveness of immunotherapy, but this is not certain. The objective of this double-blinded randomized clinical trial is to analyze, whether increased dietary fiber intake by patients with metastatic melanoma will increase the relative amount of Bifidobacterium, which in turn stimulates immune cell activity and improves the response to immunotherapy.

03

Conditions studied

  • Melanoma (Skin) Stage IV
  • Melanoma (Skin Cancer)
  • Melanoma Metastatic
  • Melanoma Advanced
  • Melanoma

Browse trials for

Keywords

  • microbiota
  • gut microbiota
  • dietary fiber
  • life-style
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cutaneous melanoma classified as irresectable stage III or stage IV disease
  • according to 1.1 criteria
  • Age ≥ 18 years
  • Starting standard-of-care treatment with ICI in
  • Written must be given
  • Able to read and understand Dutch or English
  • Able to comply with study procedures (e.g. willing to provide fecal samples)

Exclusion criteria

Exclusion Criteria:

  • Symptomatic
  • Received prior immunotherapy; previous (neo) treatment is allowed if the last administration is at least 6 months ago
  • Use of systemic medications
  • Use of laxatives up to 1 week prior to start of ICI
  • Use of supplements that alter bowel function or gut microbiota such as fibers/prebiotics, probiotics, synbiotics, or postbiotics up to 1 month prior to start of ICI
  • Use of antibiotics up to 1 months prior to start of ICI
  • Use of proton pumps inhibitors (PPI's) up to 3 months prior to start of ICI
  • Pregnant or lactating
  • Current participation in another clinical trial requiring the use of study medication
  • Has a known allergy to plants such as lettuce, sage, tarragon, chicory, artichoke, chamomile, daisy, or sunflower.
  • Has a medical history of gastrointestinal resection (appendectomy is allowed)
  • Has active inflammatory bowel disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Fiber intervention arm

    Dried chicory roots

    Dietary Supplement: Dried chicory roots

  • Placebo comparator
    Placebo arm

    iso-caloric placebo (rice-puffs)

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementDietary FiberStudies of Dietary FiberDietary Fiber pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dried chicory roots are implemented using a dosage of 22.5 gram/day resulting in 18.5 gram additional fibers a day.

    Also known as: Dietary fibers, fiber, Vezel

  • Dietary supplementPlacebo

    The control arm will receive 12.4 grams of placebo a day, isocaloric to the intervention.

    Also known as: Placebo control, Control

06

What researchers measure

Primary outcomes

  1. An increase in the relative abundance of Bifidobacterium in fecal samples.

    The primary endpoint of this study is defined as a ≥5% (e.g. from 3% to 8%) increase in the relative abundance of Bifidobacterium in fecal samples between baseline (T0) and follow-up (T1) and significant differences between the experimental arm and the control arm.

    Time frame: From baseline (T0) to 3-4 weeks (T1) after start ICI

Secondary outcomes

  1. Fecal microbiota composition

    Study the baseline and on-treatment gut microbiota composition of patients with melanoma treated with ICI +/- additional dietary fiber.

    Time frame: Measurement at baseline (T0), 3-4 weeks (T1), 3-4 months (T2), and 6-7 months (T3) after start ICI

  2. Radiological response rate to ICI

    Evaluate radiological response rates to ICI +/- additional dietary fiber, assessed by CT/PET scan per RECIST 1.1 defined as; the date of randomization to the date of disease progression or death, respectively.

    Time frame: From baseline (T0) to the first date of documented progression or date of death from any cause, wichever came first, assesed up to 5 year.

  3. Progression free survival (PFS)

    Evaluate progression-free survival defined as; the date of randomization to the date of disease progression or death, respectively.

    Time frame: From baseline (T0) to the first date of documented progression or date of death from any cause, wichever came first, assesed up to 5 year.

  4. Overall survival (OS)

    Evaluate overall survival to ICI +/- additional dietary fiber defined as; the date from randomization to date of death, respectively.

    Time frame: From baseline (T0) on, survival follow-up will be continued after study completion for a maximal of 5 years in accordance with standard-of-care follow-up.

  5. Evaluate the gastro-intestinal side effects of additional dietary fiber intake

    Evaluate the gastro-intestinal side effects of additional dietary fiber intake, according to CTCAE common criteria v 5.0.

    Time frame: From start intervention at baseline (T0) until the end of wash-out period at 6-7 months (T3) after start ICI.

Other outcomes

  1. Habitual dietary intake (Food Frequency Questionnaire)

    Nutritional intake is measured using a semi-quantitative Food Frequency Questionnaire (FFQ). Scores are calculated using the Dutch National Food Consumption tables. The FFQ will be used to evaluate habitual diet and fiber intake.

    Time frame: At baseline (T0) and at 3-4 months (T2)

  2. Physical activity level (Short QUestionnaire to ASsess Health-enhancing physical activity)

    Physical activity is measured using the Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH). The questions in the SQUASH are pre-structured in commuting, leisure time, household and work/school activities. Scores will be assigned to the different reported activities base on intensities in MET and translated to minutes of physical activity.

    Time frame: At baseline (T0) and at 3-4 months (T2)

  3. Sleep quality and duration (Pittsburgh Sleep Quality Index)

    Sleep quality is measured with the Pittsburgh Sleep Quality Index (PSQI), a 19-item questionnaire with scores ranging from 0-21. A score above 5 indicates bad sleep quality.

    Time frame: At baseline (T0) and at 3-4 months (T2)

  4. Bristol Stool Scale (BSS)

    Stool consistency is measured using the Bristol Stool Scale (BSS)

    Time frame: Measurement at baseline (T0), 3-4 weeks (T1), 3-4 months (T2), and 6-7 months (T3) after start ICI

  5. Circulating tumor DNA (ctDNA)

    ctDNA levels will be analysed to evaluate circulating tumor DNA.

    Time frame: Measurement at baseline (T0), 3-4 weeks (T1), 3-4 months (T2), and 6-7 months (T3) after start ICI

  6. Short-Chain Fatty Acids

    Fecal and Plasma SCFA's levels will be evaluated.

    Time frame: Measurement at baseline (T0), 3-4 weeks (T1), 3-4 months (T2), and 6-7 months (T3) after start ICI

  7. Sequencing mRNA in circulating immune cells

    (m)RNA will be sequenced to evaluate the transcription/gene expression in circulating immune cells.

    Time frame: Measurement at baseline (T0), 3-4 weeks (T1), 3-4 months (T2), and 6-7 months (T3) after start ICI

  8. Tumor infiltration

    Archived tumor tissue, previous to baseline (T0): Pre-interventional tumor tissue will be requested for immune cell analyses using multiplex immunohistochemistry.

    Time frame: Pretreatment

07

Study locations

1 of 2 sites recruiting
  • Medical Oncology
    Nijmegen, Gelderland 6525GA, Netherlands
    Recruiting
  • Universitair Medisch Centrum Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
    Not yet recruiting
    • Sjoukje Lubberts, dr. · Contacts.lubberts@umcg.nl
    • Kalijn Bol, dr. · ContactKalijn.Bol@radboudumc.nl
    • Kalijn Bol, dr. · Principal investigator
    • Isabel Ossekoppele, MS. · Sub investigator
    • Sjoukje Lubberts, dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2028, 21 months later.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 21 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jul 7, 2026
StartEst.
Jul 31, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
Apr 30, 2029
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07686835
Collaborators
Wageningen University and Research
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jul 31, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jul 27, 2026

Study contacts

Kalijn Bol, dr.
Contact
Kalijn.Bol@radboudumc.nl
+31 243618800
Isabel Ossekoppele, MS
Contact
Isabel.Ossekoppele@radboudumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dietary Fiber

Start the discussion